LACTOLOGY FOUNDATION

Domperidone (ATC A03FA03) is a peripheral dopamine D2 receptor antagonist with antiemetic and gastroprokinetic properties, used for nausea, vomiting and functional upper GI motility disorders. From a lactational‑toxicological standpoint, transfer into breast milk is very low and infant exposure appears minimal; the main safety concern is maternal QT‑prolongation and arrhythmic risk, especially at higher doses or in predisposed women.pubmed.ncbi.nlm.nih+5

ATC class and pharmacological profile

Domperidone belongs to the ATC class A03FA03, within “Drugs for functional gastrointestinal disorders – propulsive agents (prokinetics)”. In routine clinical use it is indicated mainly for nausea, vomiting and symptoms such as epigastric bloating and discomfort.atcddd.fhi+2

Pharmacodynamically, domperidone is a selective dopamine D2/D3 receptor antagonist that acts predominantly outside the blood–brain barrier, exerting antiemetic action via blockade of chemoreceptor trigger zone input and enhancing gastric motility via facilitation of acetylcholine release in the GI tract. It increases lower esophageal sphincter tone and accelerates gastric emptying, which underlies its prokinetic effect.wikipedia+2

Clinical indications (non‑lactation)

Clinically, domperidone is used for:

• Symptomatic treatment of nausea and vomiting of various etiologies.medpedia.framar+1
• Adjunctive management of functional dyspepsia and gastroparesis, with symptoms such as early satiety, epigastric fullness and abdominal bloating.kemh.health+1

In some countries, domperidone is approved only for short‑term use at low doses because of cardiac safety concerns. Off‑label, domperidone has been widely employed as a galactagogue to enhance milk production in mothers with insufficient lactation, especially mothers of preterm infants, although this indication is not formally approved in any country.ogmagazine+3

Regulatory status and safety concerns

Regulators have highlighted an increased risk of QT interval prolongation, ventricular arrhythmias and sudden cardiac death associated with domperidone, particularly in older patients, at doses above recommended maximums, or in the presence of other QT‑prolonging or CYP3A4‑inhibiting drugs. This has led to restriction of the maximum daily dose (commonly 30–40 mg/day in adults), limitation of treatment duration, and contraindications in patients with underlying cardiac disease or significant electrolyte disturbances.sps+4

The US FDA has not approved domperidone for any human indication, and has issued specific warnings against its use to enhance lactation because of these cardiac risks. In contrast, several other jurisdictions continue to permit domperidone use under defined conditions, including its off‑label use as a galactagogue within structured protocols.pure.eur+4

General toxicology (mother)

At therapeutic doses, non‑cardiac adverse effects include headache, dry mouth, abdominal cramps, diarrhea and hyperprolactinemia‑related effects such as galactorrhea, gynecomastia and menstrual disturbances. Extrapyramidal reactions are rare compared with centrally acting dopamine antagonists, because domperidone poorly penetrates the blood–brain barrier.thewomens+3

Cardiac toxicity is the major concern, with observational data indicating an increased risk of serious ventricular arrhythmias and sudden cardiac death, presumably via QT prolongation. Risk is higher in patients with pre‑existing QT prolongation, structural heart disease, hypokalemia or concomitant QT‑prolonging/CYP3A4‑inhibiting medications, and with doses exceeding 30–40 mg/day or prolonged treatment duration.pubmed.ncbi.nlm.nih+3

Lactational pharmacokinetics

Domperidone is highly protein‑bound (around 93%) and has low oral bioavailability (13–17%), limiting the fraction that can reach breast milk and be absorbed by the infant. Published pharmacokinetic evaluations and pooled data indicate a milk‑to‑plasma ratio generally well below 1, with relative infant doses typically between 0.01% and 0.35% of the maternal weight‑adjusted dose, even with higher‑dose or longer‑term regimens.breastfeeding-and-medication+2

Clinical studies of domperidone as a galactagogue in mothers of preterm infants have shown that domperidone concentrations in breast milk are very low, and calculated infant exposure via milk is considered minimal. In one dose–effect study, breast milk concentrations remained low across both 10 mg and 20 mg three‑times‑daily dosing, supporting the conclusion that infant systemic exposure is far below therapeutic levels used in pediatric practice.pmc.ncbi.nlm.nih+2

Documented effects in breastfed infants

Across multiple studies and observational series involving mothers taking domperidone (often 10–20 mg three times daily) to stimulate milk production, no serious adverse effects have been reported in breastfed infants. Reported follow‑up has not identified clinically significant changes in infant growth, feeding tolerance or behavior attributable to domperidone exposure via breast milk.sps+4

Professional summaries and guideline documents describe infant risk from domperidone in milk as negligible, reflecting both the very low transfer and low oral bioavailability in the infant. Domperidone has been rated as compatible with breastfeeding by several expert groups, and in some lactation risk systems (e.g. Hale) is placed in the lowest risk category (L1) for use during breastfeeding, though this does not address maternal cardiac risk.breastfeeding-and-medication+2

Use as a galactagogue

Domperidone’s prolactin‑elevating effect underlies its use as a pharmacologic galactagogue. Randomized and controlled studies in mothers of preterm infants with low milk supply show modest but clinically relevant increases in expressed milk volume with domperidone compared with placebo, particularly when combined with optimal non‑pharmacological lactation support.breastfeedingnetwork+4

However, evidence quality is moderate and long‑term data are limited; therefore, expert bodies emphasize that domperidone should only be considered after careful assessment of breastfeeding technique, frequency of milk removal and underlying causes of low supply, and then used at the lowest effective dose for a defined treatment period under medical supervision. In addition, the decision to use domperidone as a galactagogue must weigh the benefits of increased milk supply against the maternal cardiac risks, particularly in women with cardiac risk factors.abm.memberclicks+3

Risk assessment in lactation

From the perspective of the breastfed infant, domperidone exposure through breast milk is minimal: milk‑to‑plasma ratios are low, relative infant doses are well below the commonly accepted 10% threshold of concern, and no consistent adverse effects have been documented in exposed infants. Accordingly, major lactation‑focused references and national medicines handbooks describe domperidone as safe or compatible with breastfeeding when used at recommended doses, although they may simultaneously caution about its use as a galactagogue because of limited efficacy data and maternal safety concerns.breastfeedingnetwork+5

The dominant toxicity issue is maternal: QT prolongation, arrhythmogenesis and interactions with other QT‑prolonging or CYP3A4‑inhibiting medications. Thus, in lactating women, domperidone can be considered from a toxicological standpoint as low‑risk for the infant but requiring careful maternal cardiac assessment, conservative dosing (commonly 10 mg three times daily, maximum 60 mg/day), short treatment duration and ongoing clinical review.wikipedia+5

Practical recommendations during breastfeeding

When domperidone is indicated for nausea/vomiting or functional GI symptoms in a breastfeeding woman, available evidence does not require interruption of breastfeeding based solely on infant exposure through milk. Clinical practice should prioritize screening for maternal cardiac disease, review of concomitant medications, adherence to recommended doses and limiting therapy duration.ogmagazine+4

When considered as a galactagogue, domperidone should only be used after non‑pharmacological measures have been optimized, within a structured protocol that includes informed discussion of cardiac risks, baseline risk stratification, and planned discontinuation once milk supply improves. Routine additional monitoring of the infant is usually unnecessary, though closer observation may be justified in preterm or medically complex infants, reflecting general principles for drug exposure via breast milk rather than domperidone‑specific concerns.mayoclinic+5

Toxicological lactation category (Dimitar Kehayov)

Available pharmacokinetic data show low domperidone transfer into human milk and very low relative infant doses, with no evidence of clinically relevant toxicity in breastfed infants at usual maternal doses. Therefore, within your system, domperidone (A03FA03) is best classified as:pmc.ncbi.nlm.nih+2

Toxicological lactation category II (Dimitar Kehayov) – the drug and/or its metabolites are excreted into breast milk, but the milk:plasma ratio is very low and the quantities transferred cannot generate toxic reactions in the newborn at standard maternal doses; breastfeeding does not need to be discontinued on toxicological grounds, although clinical use is constrained by maternal cardiac risk.